Exalgo

Exalgo is a brand name of hydromorphone, approved by the FDA in the following formulation(s):

EXALGO (hydromorphone hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: March 1, 2010
  
  Strength(s): 12MG, 16MG ^[RLD], 8MG
  

Has a generic version of Exalgo been approved?

No. There is currently no therapeutically equivalent version of Exalgo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exalgo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Hydromorphone therapy
  Patent 5,702,725
  Issued: December 30, 1997
  Inventor(s): Merrill; Sonya & Ayer; Atul Devdatt & Chadha; Navjot & Kuczynski; Anthony L.
  Assignee(s): Alza Corporation
  A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
  
  Patent expiration dates:
  
  
  • July 7, 2014
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN
    ✓ 
    Drug product
  
  



• 
  Hydromorphone therapy
  Patent 5,914,131
  Issued: June 22, 1999
  Inventor(s): Merrill; Sonya & Ayer; Atul D. & Chadha; Navjot & Kuczynski; Anthony L.
  Assignee(s): ALZA Corporation
  A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
  
  Patent expiration dates:
  
  
  • July 7, 2014
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 1, 2013 - NEW DOSAGE FORM
  
  

See also...

• Exalgo Consumer Information (Drugs.com)
• Exalgo Consumer Information (Wolters Kluwer)
• Exalgo Consumer Information (Cerner Multum)
• Exalgo Advanced Consumer Information (Micromedex)
• Hydromorphone Consumer Information (Wolters Kluwer)
• Hydromorphone Extended-Release Consumer Information (Wolters Kluwer)
• Hydromorphone Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Hydromorphone High-Potency Consumer Information (Wolters Kluwer)
• Hydromorphone Liquid Consumer Information (Wolters Kluwer)
• Hydromorphone Suppository Consumer Information (Wolters Kluwer)
• Hydromorphone Tablets Consumer Information (Wolters Kluwer)
• Hydromorphone Consumer Information (Cerner Multum)
• Hydromorphone injection Consumer Information (Cerner Multum)
• Hydromorphone rectal Consumer Information (Cerner Multum)
• Hydromorphone Advanced Consumer Information (Micromedex)
• Hydromorphone Injection Advanced Consumer Information (Micromedex)
• Hydromorphone Hydrochloride AHFS DI Monographs (ASHP)